These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 11261530)

  • 21. Orlistat: a review of its use in the management of obesity.
    Hvizdos KM; Markham A
    Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of orlistat in weight management.
    Marks S
    Aust Fam Physician; 2001 Apr; 30(4):335-8. PubMed ID: 11355219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents.
    Zhi J; Moore R; Kanitra L
    J Am Coll Nutr; 2003 Oct; 22(5):357-62. PubMed ID: 14559927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapeutic options for overweight adolescents.
    Dunican KC; Desilets AR; Montalbano JK
    Ann Pharmacother; 2007 Sep; 41(9):1445-55. PubMed ID: 17652127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
    Smith SR; Stenlof KS; Greenway FL; McHutchison J; Schwartz SM; Dev VB; Berk ES; Kapikian R
    Obesity (Silver Spring); 2011 Sep; 19(9):1796-803. PubMed ID: 21720429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity.
    Cahill A; Lean ME
    Aliment Pharmacol Ther; 1999 Aug; 13(8):997-1002. PubMed ID: 10468673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP; Avenell A; Broom J; Whitehead J
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on orlistat in the management of patients with obesity.
    Curran MP; Scott LJ
    Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.
    Shirai K; Fujita T; Tanaka M; Fujii Y; Shimomasuda M; Sakai S; Samukawa Y
    Adv Ther; 2019 Jan; 36(1):86-100. PubMed ID: 30535651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit-risk assessment of orlistat in the treatment of obesity.
    Sumithran P; Proietto J
    Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Orlistat (Xenical)].
    Crenier L; Sternon J
    Rev Med Brux; 1999 Jun; 20(3):159-63. PubMed ID: 10429540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
    Karhunen L; Franssila-Kallunki A; Rissanen P; Valve R; Kolehmainen M; Rissanen A; Uusitupa M
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1567-72. PubMed ID: 11126207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orlistat: current status in clinical therapeutics.
    McClendon KS; Riche DM; Uwaifo GI
    Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orlistat. No hurry...
    Can Fam Physician; 1999 Oct; 45():2331-3, 2336-8, 2343-5 passim. PubMed ID: 10540693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
    Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.